A study of over 3,000 cancer patients has revealed that cancer pain continues to go under-treated or untreated altogether in about one-third of patients.
This despite a major study published in 1994 that drew attention to the undertreatment of cancer pain and was so influential that it changed the published guidelines for cancer pain management by the Department of Health and Human Services.
The 1994 study had determined that as many as 42 percent of cancer patients were not receiving pain management, for various reasons, and that it was an aspect of cancer care that required immediate attention from clinicians.
Almost two decades later, the improvement appears to have been modest at best. The latest study, by researchers from MD Anderson Cancer Center and published in the Journal of Clinical Oncology, also revealed a racial angle, namely that blacks and Hispanics were twice as likely as Caucasians not to be prescribed pain medication.
Source: Houston Chronicle
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...